DefiniGEN licences lung stem cell technology from Cambridge University

Cambridge stem cell products pioneer DefiniGEN has strengthened its IP portfolio with a licence for cutting edge lung stem cell technology from the University of Cambridge. The technology will be used by DefiniGEN to develop new, optimised cell products …

[Read the full article here]

Comments are closed.